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Background: Microtubules have been one of the most effective targets for the development of anticancer agents.
Cancer cells treated by these agents are characterized by cell arrest at G2/M phase. Microtubule-targeting drugs are,
therefore, referred to as antimitotic agents. However, the clinical application of the current antimitotic drugs is
hampered by emerging drug resistance which is the major cause of cancer treatment failure. The clinical success of
antimitotic drugs and emerging drug resistance has prompted a search for new antimitotic agents, especially those
with novel mechanisms of action. The aim of this study was to determine whether microtubules can be
S-glutathionylated in cancer cells and whether the glutathionylation will lead to microtubule dysfunction and cell
growth inhibition. The study will determine whether microtubule S-glutathionylation can be a novel approach for
antimitotic agents.
Methods: 2-Acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanylcarbonylamino)phenyl carbamoylsulfanyl]
propionic acid (2-AAPA) was used as a tool to induce microtubule S-glutathionylation. UACC-62 cells, a human
melanoma cell line, were used as a cancer cell model. A pull-down assay with glutathione S-transferase
(GST)-agarose beads followed by Western blot analysis was employed to confirm microtubule S-glutathionylation.
Immunofluorescence microscopy using a mouse monoclonal anti-α-tubulin-FITC was used to study the effect of the
S-glutathionylation on microtubule function; mainly polymerization and depolymerization. Flow cytometry was
employed to examine the effect of the S-glutathionylation on cell cycle distribution and apoptosis. Cell
morphological change was followed through the use of a Zeiss AXIO Observer A1 microscope. Cancer cell growth
inhibition by 2-AAPA was investigated with ten human cancer cell lines.
Results: Our investigation demonstrated that cell morphology was changed and microtubules were
S-glutathionylated in the presence of 2-AAPA in UACC-62 cells. Accordingly, microtubules were found
depolymerized and cells were arrested at G2/M phase. The affected cells were found to undergo apoptosis. Cancer
growth inhibition experiments demonstrated that the concentrations of 2-AAPA required to produce the effects on
microtubules were compatible to the concentrations producing cancer cell growth inhibition.
Conclusions: The data from this investigation confirms that microtubule S-glutathionylation leads to microtubule
dysfunction and cell growth inhibition and can be a novel approach for developing antimitotic agents.* Correspondence: Xiangming.Guan@sdstate.edu
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Figure 1 Chemical structure of 2-AAPA.
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Microtubules are involved in a diverse range of cellular
functions, including motility, maintenance of cell shape,
adhesion, intracellular trafficking of macromolecules and
organelles, and, most importantly, mitosis [1-4]. The role
that microtubules play in mitosis makes them one of the
most highly validated targets for the development of
chemotherapeutic drugs against rapidly dividing cancer
cells [5]. Evidence has shown that subtle alteration in
the structure of microtubules can cause improper at-
tachment of chromosomes and impair the tension,
which in turn signals the spindle checkpoint to prevent
anaphase onset and chromosome segregation. The cell
eventually exits mitosis aberrantly and undergoes apop-
tosis [5]. The effectiveness of microtubule-targeting
drugs has been demonstrated by the extensive clinical
use of several vinca alkaloids (vinblastine, vincristine,
etc.) and taxanes (paclitaxel and docetaxel) for the treat-
ment of a wide variety of human cancers [5]. Cancer
cells treated with these agents are characterized by cell
cycle arrest at G2/M phase. Microtubule-targeting drugs
are, therefore, frequently referred to as antimitotic agents.
Structurally, microtubules are composed of similar
50 kDa α/β-tubulin heterodimers that share 40% se-
quence identity with almost identical three-dimensional
structures [6]. Formation of microtubules involves
reversible, noncovalent polymerization of repeating α/β-
tubulin subunits that bind head to tail into protofila-
ments [7-9]. Tubulins are rich in thiol groups with a
total of 20 free thiol groups per tubulin dimer (12 in
α-tubulin and 8 in β-tubulin) [10,11]. These thiol
groups are critical to tubulin polymerization or micro-
tubule formation and function [12]. Loss of these thiol
groups inevitably affects tubulin polymerization as
observed in the oxidation [13,14] or alkylation [11] of
these thiol groups. Mechanistically, most current antimi-
totic agents are classified into one of three classes based
on their interactions with microtubules [15]. The first
class of antimitotic agents, exemplified by paclitaxel,
interact with the taxane binding site (M-loop) and cause
microtubule stabilization [15]. The second class includes
the vinca alkaloids which inhibit tubulin assembly by
interacting at the interface between α,β-dimers resulting
in microtubule depolymerization. The third class of
compounds interact at the colchicine-binding site, the
interface of the α,β-dimers, and prevent assembly of
tubulin into microtubules [15].
In our earlier study with 2-acetylamino-3-4-(2-acetyla-
mino-2-carboxyethylsulfanylcarbonylamino)phenylcarba-
moylsulfanyl]propionic acid (2-AAPA, Figure 1) to
modulate intracellular thiol oxidative stress, we found
that 2-AAPA caused cell morphological change and cell
detachment indicating that the cellular cytoskeletal struc-
ture was affected [16,17]. Further, 2-AAPA was shown toinduce protein S-glutathionylation [16,17]. Protein S-
glutathionylation is a process where a glutathione mol-
ecule (GSH) is connected to a protein thiol (PSH) through
a disulfide bond (-S-S-) (Scheme 1) [13,18,19]. In view of
the critical role thiol groups play in microtubule func-
tion and the rich content of thiol groups present in the
microtubule structure, we suspected that 2-AAPA might
induce microtubule S-glutathionylation and the S-
glutathionylation might cause dysfunction of microtu-
bules. If confirmed, microtubule S-glutathionylation
could be a novel approach for the development of anti-
mitotic agents which exhibit a different mechanism of
action than the currently employed antimitotic drugs.
These agents will be helpful in overcoming the emerging
drug resistance problem associated with vinca alkaloids
and taxanes. The aim of this study was to investigate
whether microtubule can be S-glutathionylated in cancer
cells and whether the S-glutathionylation leads to micro-
tubule dysfunction and cell growth inhibition.
Methods
Materials and cell lines
2-AAPA was synthesized as described previously [20].
2-AAPA is currently also available from Sigma-
Aldrich Chemical Co. (Milwaukee, WI). p-[3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
(MTT), ethylenediaminetetraacetic acid (EDTA), N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES),
2-amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride
(Tris–HCl) buffer, 4′,6-diamidino-2-phenylindole (DAPI),
paclitaxel, vinblastine, propidium iodide (PI), RNase, horse-
radish peroxidase, sodium dodecyl sulfate (SDS), Triton-X-
100, and mouse monoclonal anti-α-tubulin-FITC were
obtained from Sigma-Aldrich Chemical Co. (Milwaukee,
WI). The Vybrant™ Apoptosis Assay Kit #2 was purchased
from Molecular Probes (Carlsbad, CA). Dulbecco’s phos-
phate buffered saline (DPBS), fetal bovine serum (FBS), mini-
mum essential medium (MEM), phosphate buffered saline
(PBS), RPMI-1640, and trypsin-EDTA were from Mediatech,
Inc. (Herndon, VA). Dulbecco’s modified eagle’s medium

















Scheme 1 Protein S-glutathionylation.
Chen et al. BMC Cancer 2012, 12:245 Page 3 of 11
http://www.biomedcentral.com/1471-2407/12/245Collection (ATCC). Sulfosalicylic acid was purchased from J.
T. Baker Chemical Co. (Phillipsburg, NJ). Antibodies of α-
tubulin and β-tubulin, secondary antibodies and GST-agarose
beads were from Santa Cruz Biotechnology (Santa Cruz, CA).
ECL Plus Kit was purchased from Amersham Biosciences
(Piscataway, NJ). Other reagents were obtained in their high-
est purity grade available commercially. Cells were cultured in
MEM, DMEM or RPMI 1640 growth medium supplemented
with 10% FBS, 100 units/mL of penicillin (Mediatech, Inc.,
Herndon, VA) and 100 μg/mL of streptomycin (Mediatech,
Inc., Herndon,VA) in a humidified atmosphere containing 5%
CO2 at 37°C. Human cancer cell linesNCI/ADR-RES (ovarian
cancer), OVCAR-3 (ovarian cancer), UACC-62 (melanoma),
NCI-H226 (lung cancer), PC-3 (prostate cancer), and UO-31
(renal carcinoma)were obtained from theNational Cancer In-
stitute (NCI); A-431 (epidermoid carcinoma), SK-MEL-2
(melanoma), and MCF7 (breast cancer) were obtained from
ATCC. GC3/c1 human colon adenocarcinoma cells were
kindly provided byDr. Peter J. Houghton of St. Jude Children’s
ResearchHospital,Memphis,Tennessee.
In vitro cytotoxicity evaluation
2-AAPA was tested in vitro for cytotoxicity against NCI/
ADR-RES, OVCAR-3, UACC-62, UO-31, NCI-H226,
A431, MCF7, PC-3, SK-MEL-2 and GC3/c1 cells in 96-
well plates using MTT assay to determine IC50 values. In
brief, exponentially growing cells were plated in 96-well
plates (1500, 2000, 1500, 2000, 1800, 1000, 2500, 2000,
2000 and 5000 cells/well for NCI/ADR-RES, OVCAR-3,
UACC-62, UO-31, NCI-H226, A431, MCF7, PC-3, SK-
MEL-2 and GC3/c1 cells respectively) in various media
(RPMI 1640 for NCI/ADR-RES, OVCAR-3, UACC-62,
UO-31, NCI-H226, PC-3, SK-MEL-2 and GC3/c1, MEM
supplemented with 10 μg/mL insulin for MCF7, and
DMEM for A431 respectively). The cells were allowed to
attach at 37°C in a humidified atmosphere of 5% CO2
for 24 h, and then the medium was replaced with the
medium containing various concentrations of 2-AAPA.
Cells were exposed to the medium containing 2-AAPAfor 6 days at the same incubation condition. After the
treatment, MTT assay was performed to determine IC50
values.
Determination of protein S-glutathionylation by HPLC
Protein samples from UACC-62 cells treated with 2-
AAPA were prepared and S-glutathionylation was deter-
mined by the HPLCmethod described by Chen et al. [16].
Determination of tubulin S-glutathionylation by a
pull-down assay
Protein was extracted from UACC-62 cells using the
method described by Chen et al. [16] with minor modifi-
cation. Briefly, UACC-62 cells (5 million) were detached
by trypsinization and treated with 100 μM 2-AAPA at
37oC for 20 min. After washing with ice-cold PBS, one
milliliter of ice-cold sulfosalicylic acid aqueous solution
(3%, w/w) was added to the cells. The lysed cells were
centrifuged at 15000 × g for 1 min. The supernatant was
discarded and the lysate pellets were washed thoroughly
with the sulfosalicylic acid aqueous solution (1 mL×3)
to ensure that no residual non-protein thiols were left.
Then the pellets were washed twice with Tris–HCl buf-
fer (50 mM, pH 7.4) containing 5 mM EDTA. The pel-
lets were collected by centrifugation at 15000 × g for
1 min and solubilized in 200 μL of denaturing lysis
buffer with 1% SDS without dithiothreitol prepared as
described by Bonifacino et al. [21]. The protein solution
was then heated at 100°C for 5 min. The supernatant
was collected after centrifugation at 15000 × g for 5 min
and stored at −20°C for future use. For tubulin S-glu-
tathionylation determination, 500 μg of protein sample
was incubated with 40 μL of GST- agarose beads in
a total of 1 mL of HEPES buffer containing 1% Triton
X-100 overnight at 4°C on a platform rocker. GST-
agarose beads were collected by centrifugation at
5,000 × g for 5 min at 4°C and gently washed with PBS
followed by centrifugation to collect the beads. The
wash was repeated four times. After the final wash,
Table 1 Anticancer activity evaluation of 2-AAPA against
various human cancer cells
Cell line IC50* (μM)
NCI/ADR-RES (ovarian cancer) 28 ± 1
OVCAR-3 (ovarian cancer) 33 ± 2
UACC-62 (melanoma) 22 ± 1
SK-MEL-2 (melanoma) 40 ± 9
NCI-H226 (lung cancer) 68 ± 4
UO-31 (kidney cancer) 44 ± 10
A431 (skin cancer) 73 ± 4
PC-3 (prostate cancer) 50 ± 12
MCF7 (breast cancer) 75 ± 5
GC3/c1 (colon cancer) 42 ± 1
*IC50: concentration of a drug required to reduce cell growth by 50%. Cells
were treated with 2-AAPA for 6 days. Cell survival rates were determined by
the MTT assay. IC50 values were derived from corresponding dose–response
curves. The data are presented as the mean ± SD of three independent
experiments.
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pellets were resuspended in 60 μL of 2× non-reducing
electrophoresis sample buffer. Samples were boiled for
5 min at 100°C and centrifuged at 15000 × g at 4°C for
5 min. The S-glutathionylated tubulin proteins in the
supernatant were subjected to SDS- PAGE. Then the
proteins in gels were transferred to nitrocellulose mem-
branes and probed with the appropriate dilution of pri-
mary α- or β-tubulin antibodies followed by appropriate
horseradish peroxidase (HRP) conjugated secondary
antibody and ECL Plus detection kit. The bands were
visualized using a UVP Biochem Gel Documentation
system (UVP, Inc., Upland, CA).
Cell morphological change
Cultured UACC-62 cells were treated with 50 μM 2-
AAPA at 37oC. Live cell images were taken by a Zeiss
AXIO Observer A1 microscope equipped with a
temperature-controlled stage at 37°C.
Indirect immunofluorescence microscopy
UACC-62 cells were incubated with 2-AAPA at 37°C in
a humidified atmosphere of 5% CO2 for various time
periods and then fixed in 4% paraformaldehyde at room
temperature for 1 h. The cells were washed thrice with
PBS and incubated with cell permeable solution (0.1%
Na-citrate, 0.1% Triton-X-100 in 1 × PBS) at room tem-
perature for 1 h. After incubation with the blocking so-
lution (PBS containing 5% bovine serum albumin)
overnight at 4°C, microtubules were visualized using a
mouse monoclonal anti-α-tubulin-FITC (1:1,000), and
nuclei were stained with DAPI (1 μg/mL). Fluorescent
images were taken with an Olympus AX70 fluorescence
microscope. Paclitaxel and vinblastine were employed as
positive controls for microtubule stabilization and
microtubule depolymerization, respectively.
Analysis of cellular DNA content by flow cytometry
UACC-62 cells (1 million) were plated in 100 mm cul-
ture dishes in RPMI 1640 medium for 24 h attachment
at 37oC in a humidified atmosphere of 5% CO2, and then
treated with 15 mL of RPMI 1640 medium containing
various concentrations of 2-AAPA for 12 h or 24 h at
the same incubation condition. At the end of treatment,
adherent cells were harvested and washed twice with
ice-cold PBS. One million cells of each sample were
fixed with 70% ethanol in DPBS at 4°C. The fixed cells
were then centrifuged (700 × g, 5 min) and washed with
staining buffer. After the wash, the samples were centri-
fuged (700 × g, 5 min), and the pellets were treated with
100 μL of RNase A (1 mg/mL) for 30 min at 37°C. After
incubation, 900 μL of staining buffer was added to the
samples to bring the volume to 1 mL followed by ad-
dition of 20 μL of propidium iodide (PI) (1 mg/mL). Thesample was then incubated in the dark at room tem-
perature for 30 min before being analyzed with a BD
FACScan™ flow cytometer (BD Biosciences, San Jose, CA)
using CellQuest Software (BD Biosciences, San Jose, CA).
Apoptosis assay by flow cytometry
UACC-62 cells (0.2 million) were plated in 25 cm2 flasks
with RPMI 1640 growth medium. After a 24 h-
attachment at 37oC in a humidified atmosphere of 5%
CO2, UACC-62 cells were treated with RPMI 1640
growth medium containing various concentrations of 2-
AAPA. Annexin V/PI staining was performed using the
Vybrant™ Apoptosis Assay Kit #2 according to the man-
ufacture’s instruction. The samples were analyzed with a
BD FACScan flow cytometer.
Statistical analysis
Data were analyzed with INSTAT software (Graph Pad,
San Diego, CA). ANOVA followed by Tukey’s post test
was applied to compare the statistical difference between
2-AAPA treatment groups and untreated controls. Sig-
nificance in all experiments was considered at P < 0.05.
Values were expressed as mean ± the standard deviation
of the mean.
Results
In vitro cytotoxicity of 2-AAPA against various human
cancer cells
The cell growth inhibition of 2-AAPA was evaluated
with various human cancer cell lines. As demonstrated
in Table 1, 2-AAPA exhibited similar IC50 values, in the
range of 22 to 75 μM, against all the tested cancer cells
revealing that the cytotoxicity is not cancer cell type-
dependent. Based on the IC50 values, UACC-62 appears
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therefore, was selected for further study.Figure 3 2-AAPA induces tubulin S-glutathionylation. UACC-62
cells were treated with 100 μM 2-AAPA for 20 min and
S-glutathionylated proteins were captured by a pull-down assay
using GST-agarose beads followed by Western blot analysis.
α- and β-Tubulins were detected as described in the method.Protein S-glutathionylation induced by 2-AAPA
Previously, protein S-glutathionylation was detected in
both CV-1 (monkey kidney cells) and OVCAR-3 cells
treated with 100 μM 2-AAPA [16,17]. Before checking
whether microtubules were S-glutathionylated in UACC-
62 cells, we first determined whether proteins were S-
glutathionylated in the presence of 2-AAPA. UACC-62
cells were treated with 100 μM 2-AAPA for 20 min and
protein S-glutathionylation was determined as reported
[16]. Protein S-glutathionylation (2.19 ± 0.30 nmol GSH/
million cells) was detected in UACC-62 cells. The
amount of protein S-glutathionylation by 2-AAPA
induced in UACC-62 cells was similar to that obtained
from OVCAR-3 cells confirming 2-AAPA’s ability to in-
duce cellular protein S-glutathionylation. UACC-62 cells
were then treated with 50 μM 2-AAPA, a concentra-
tion close to the IC50 value, to determine the time
profile of protein S-glutathionylation. The results are
presented in Figure 2. Protein S-glutathionylation was
observed at 5 min and reached the maximum in
10 min. At 1 h, protein S-glutathionylation was found
to be about 40% of the maximum and continued to
fall afterwards (Figure 2).Determination of microtubule S-glutathionylation
Due to the quantity limitation of microtubules in cells, our
HPLCmethod for protein S-glutathionylation was not sen-
sitive enough to detect microtubule S-glutathionylation.






































Figure 2 2-AAPA induces protein S-glutationylation in UACC-62 cells.
periods and protein S-glutathionylation was determined by the HPLC meth
mean ± SD of triplet determination of one set of samples. No protein S-glu
were conducted at 5 min and 4 h respectively. No S-glutathionylation wasa pull-down assay reported by Cheng and co-workers
[22] with modification.
Cheng and co-workers used biotinylated glutathione
S-transferase (GST) from Schistosoma japonicum to de-
tect the glutathione moiety of S-glutathionylated protein.
Since biotinylated GST was not commercially avail-
able, we decided to use GST-agarose beads containing
the GST from the same species as an alternative. S-
Glutathionylated proteins were pulled down by GST-
agarose beads followed by the Western blot analysis with
the antibodies of α-tubulin and β-tubulin. Figure 3 shows
that both α-tubulin and β-tubulin were S-glutathionylated
when UACC-62 cells were treated with 100 μM 2-AAPA
for 20 min while no S- glutathionylated tubulins were
detected in the controls. The densities of the bands are
consistent with the fact that α-tubulin has more thiol
groups than β-tubulin.20 min 1 h 2 h 4 h Ctrl-2
UACC-62 cells were treated with 50 μM 2-AAPA for different time
od described by Chen et al. [16]. The results were presented as the
tathionylation was detected in untreated cells. Control 1 and control 2
detected in both control 1 and control 2.
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To confirm that microtubule structure was affected by
the S-glutathionylation, the microtubule network was
examined via immunofluorescence microscopy. As
shown in Figure 4a, microtubules formed an intactFigure 4 2-AAPA induces microtubule depolymerization in UACC-62 c
2-AAPA for 12 h (a), or with 50 μM 2-AAPA for indicated time periods (b), f
analysis with an anti-α-tubulin-FITC. Nuclei were stained with DAPI. Paclitax
stabilization and microtubule depolymerization respectively. The data are dnetwork with fine mesh and filaments in untreated
cells, while a significant reduction of microtubule dens-
ity was observed in 2-AAPA-treated cells. Microtubules
in treated cells were found dispersed and lost their ori-
ginal linear filamentous structure with disorganizedells. UACC-62 cells were treated with the indicated concentrations of
ollowed by fixation, permeabilization and indirect immunofluorescent
el and vinblastine were employed as positive controls for microtubule
erived from one of the three independent experiments.
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blastine, a microtubule depolymerizing antimitotic drug,
and that of paclitaxel, a microtubule stabilizing antimito-
tic drug, the same experiments were conducted with vin-
blastine and paclitaxel. Figure 4a shows that the effect of
2-AAPA on microtubules was similar to that of vinblast-
ine revealing that 2-AAPA depolymerized microtubules.
The time-dependent effect of 2-AAPA on microtubule
structure was further determined by treating UACC-62
cells with 50 μM 2-AAPA for different time periods
(Figure 4b). Significant microtubule depolymerization
was observed at 5 min. The deploymerization reached a
maximum in 20 min. Recovery was observed at one hour.
The time profile of microtubule depolymerization
(Figure 4b) appears to match well with that of protein
S-glutathionylation (Figure 2).Cell morphological change
Consistent with the microtubule network being affected,
the morphology of the cells was found to be changed.
When UACC-62 cells were treated with 50 μM 2-AAPA,
the morphology changes were observed as early as
6 min and involved more than 90% cells at the end of
20 min (Figure 5).Figure 5 Effect of 2-AAPA on cell morphological changes in UACC-62
cells undergoing morphological changes are marked by red arrows.Effects on the cell cycle
To further confirm microtubule function is being
affected, the effect on the cell cycle was investigated.
After being treated with 2-AAPA (35 and 50 μM),
UACC-62 cells were found to be arrested in the G2/M
phase (Figure 6) which is consistent with microtubule
depolymerization.Effects on apoptosis
All anti-microtubule agents identified to date are known
to induce apoptotic cell death in cancer cells [23]. We
evaluated the effect on apoptosis by treating UACC-62
cells with different concentrations of 2-AAPA for 12 h
and 24 h (Figure 7). At 20 μM and 35 μM, 2-AAPA
induced apoptosis in a dose- and time-dependent man-
ner (P <0.05).Discussion
Antimitotic agents which induce tumor cell mitotic ar-
rest and apoptosis are one of the most important classes
of cancer chemotherapeutic agents [24]. However, the
clinical application of the current antimitotic drugs is
hampered by the problems of undesired side effects,
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Figure 6 Effect of 2-AAPA on cell cycle distribution in UACC-62 cells. The histograms of UACC-62 cells treated with different concentrations
of 2-AAPA for 24 h and 48 h are presented (a). The bar presentations reflects the quantification of cell cycle distribution at 24 h (b) and 48 h (c)
respectively. Results are presented as the mean ± SD of three independent experiments. *, P< 0.05 indicates statistical significance in 2-AAPA
treated groups as compared to the control.
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ging drug resistance is of particular concern since it is
the major cause of cancer treatment failure. Extensive
efforts have been made to search for agents which can
effectively interfere with microtubule function, especially
those with a novel mechanism of action [25,26].
In this study, we have demonstrated that microtubules
can be S-glutathionylated. In view of the critical role of
the thiol functional groups in microtubule polymeriza-
tion, it is reasonable to suggest that the microtubule
S-glutathionylation led to microtubule depolymeri-
zation. To confirm this, a correlation study between
protein S-glutathionylation and microtubule depoly-
merization was conducted. Ideally, the correlation
study should be conducted between microtubule S-
glutathionylation and microtubule depolymerization.
As indicated earlier, the analytical method for thequantification of protein S-glutathionylation is not sen-
sitive enough to quantify microtubule S-glutathionyla-
tion. As presented in the result section, there was a clear
correlation between protein S-glutathionylation and
microtubule depolymerization. The time profile of
microtubule depolymerization matched well with that of
protein S-glutathionylation supporting that microtubule
S-glutathionylation caused microtubule depolymeri-
zation. It is noted that protein S-glutathionylation in-
creased initially in the first 10 min and then subsided
after 20 min. Similar phenomena were observed earlier
in CV-1 cells and believed to be a result of a recovered
glutathione reductase activity [17]. The malfunction of
microtubules was also reflected in the cell morphology
and cell cycle distribution; cells were found to experience


















































Figure 7 Effect of 2-AAPA on the induction of apoptosis in UACC-62 cells. UACC-62 cells were treated with different concentrations of
2-AAPA for 12 h and 24 h and stained with Annexin V and PI. Apoptotic cells were analyzed by flow cytometry (a). The percentages of apoptotic
cells are presented for 12 h (b) and 24 h (c) treatment. Results are presented as the mean ± SD of three independent experiments.
*, P< 0.05 indicates statistical significance in 2-AAPA treated groups as compared to the control.
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reversible oxidative modification of PSH as a response of
the cell to oxidative stress [27-31]. As indicated earlier,
protein S-glutathionylation involves a mixed disulfide
bond (P-S-S-G) formation between PSH and GSH. Once
oxidative stress is over, the P-S-S-G will be reduced
back to PSH enzymatically by glutaredoxin (Grx)
[9,27,29,32-34]. The rich thiol content of microtubules
likely makes them susceptible to S-glutathionylation.
Although the exact mechanism by which 2-AAPA
produces protein S-glutathionylation, including micro-
tubule S-glutathionylation, is not clear, our earlier data
showed that protein S-glutathionylation induced by 2-
AAPA correlates with the formation of the oxidized
form of glutathione (GSSG) [35]. Consistently, Carletti
and co-workers [36] recently reported that an increasein GSSG in neuron cells produced significant tubulin
S-glutathionylation. They also determined that tubulin
S-glutathionylation inhibited tubulin polymerization.
Along the same line, we also found that an increase in
intracellular GSSG, achieved through delivery of GSSG
into cells by a liposome delivery method, produced signifi-
cant protein S-glutathionylation and similar microtubule
depolymerization in NCI-H226 cells as observed in this in-
vestigation (unpublished data from this laboratory). Taken
together, we believe that microtubule S-glutathionylation
causes microtubule depolymerization. The malfunction of
microtubules led to cell morphological changes, cell cycle
arrest at G2/M phase, and eventually apoptosis.
Finally, the cancer growth inhibition effects of 2-
AAPA against other human cancer cell lines were
determined. The IC50 determination reveals that 2-AAPA
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are close to the concentrations that affect microtubule
function suggesting that microtubule S-glutathionylation
is likely the contribution to cancer cell growth inhibition.
Conclusions
In summary, our investigation provides evidence demon-
strating that microtubule S-glutathionylation will lead to
microtubule depolymerization, cell cycle arrest at G2/M
phase, and apoptosis. This mechanism of action is differ-
ent than those of currently used antimitotic agents. This
finding suggests that microtubule S-glutathionylation
can be potentially used as a novel approach to develop
new classes of antimitotic agents which can be
complimentary to the existing antimitotic agents.
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